Symbol | Exchange | Currency |
|---|
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of...
Benzinga - Piper Sandler cut the price target for CS Disco, Inc. (NYSE: LAW) from $11 to $7.5. Piper Sandler analyst Arvind Ramnani downgraded the stock from Overweight to...
MannKind (NASDAQ:MNKD) reported Q4 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $36.06 million versus the consensus estimate...
2022 Total Revenues of $100 million; +32% vs. 20212022 Royalties from Tyvaso DPI of $16 million; 4Q 2022 of $9 million4Q 2022 Commercial Products Net Revenue of $17 million;+54%...
Inhaled Technosphere® Insulin (TI) lowered peak glucose levels 30 minutes faster than injectable rapid-acting insulin delivered through an AID insulin pump and significantly...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 fourth quarter and full year financial...
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
| Average | 6.667 (+67.093% Upside) |
| High | 8.000 |
| Low | 5.000 |
| Price | 3.990 |
| No. of Analysts | 6 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Buy | Sell | Sell | Strong Sell | Strong Buy |
| Summary | Buy | Neutral | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 151.80 | 153.40 | 151.40 | -1.60 | -1.04% | 2.60M | London | |||
| 215.00 | 221.00 | 210.00 | -5.00 | -2.27% | 624.35K | London | |||
| 133.90 | 137.74 | 130.06 | -5.88 | -4.21% | 122.87M | London | |||
| 103.05 | 104.30 | 102.30 | -1.70 | -1.62% | 24.54M | London | |||
| 222.50 | 224.50 | 220.00 | -2.50 | -1.11% | 312.84K | London | |||
| 1,030.00 | 1,030.00 | 1,030.00 | 0.00 | 0.00% | 30.79K | London | |||
| 0.1275 | 0.132 | 0.1305 | -0.0085 | -6.25% | 382.90M | London | |||
| 1,100.00 | 1,160.00 | 1,079.00 | -40.00 | -3.51% | 289.75K | London | |||
| 478.50 | 492.00 | 473.00 | -12.00 | -2.45% | 66.67K | London | |||
| 88.58 | 90.78 | 88.16 | -2.22 | -2.44% | 55.26M | London | |||
| 12.25 | 12.70 | 12.00 | +0.25 | +2.08% | 738.23K | London | |||
| 0.12 | 0.13 | 0.13 | 0.00 | 0.00% | 0.00 | Aquis Exchange | |||
| 362.50 | 362.50 | 362.50 | -2.50 | -0.69% | 50.84K | London | |||
| 262.60 | 280.00 | 261.60 | -10.70 | -3.92% | 1.30M | London | |||
| 94.50 | 92.40 | 92.40 | +2.10 | +2.27% | 193.60K | London |